JP2022518282A5 - - Google Patents

Info

Publication number
JP2022518282A5
JP2022518282A5 JP2021543170A JP2021543170A JP2022518282A5 JP 2022518282 A5 JP2022518282 A5 JP 2022518282A5 JP 2021543170 A JP2021543170 A JP 2021543170A JP 2021543170 A JP2021543170 A JP 2021543170A JP 2022518282 A5 JP2022518282 A5 JP 2022518282A5
Authority
JP
Japan
Prior art keywords
sequence
sequence number
composition
composition according
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021543170A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518282A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/014845 external-priority patent/WO2020154540A1/en
Publication of JP2022518282A publication Critical patent/JP2022518282A/ja
Publication of JP2022518282A5 publication Critical patent/JP2022518282A5/ja
Priority to JP2024229904A priority Critical patent/JP2025060876A/ja
Withdrawn legal-status Critical Current

Links

JP2021543170A 2019-01-23 2020-01-23 抗cd38結合ドメイン Withdrawn JP2022518282A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024229904A JP2025060876A (ja) 2019-01-23 2024-12-26 抗cd38結合ドメイン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962795855P 2019-01-23 2019-01-23
US62/795,855 2019-01-23
PCT/US2020/014845 WO2020154540A1 (en) 2019-01-23 2020-01-23 Anti-cd38 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024229904A Division JP2025060876A (ja) 2019-01-23 2024-12-26 抗cd38結合ドメイン

Publications (2)

Publication Number Publication Date
JP2022518282A JP2022518282A (ja) 2022-03-14
JP2022518282A5 true JP2022518282A5 (https=) 2023-02-01

Family

ID=69740548

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021543170A Withdrawn JP2022518282A (ja) 2019-01-23 2020-01-23 抗cd38結合ドメイン
JP2024229904A Pending JP2025060876A (ja) 2019-01-23 2024-12-26 抗cd38結合ドメイン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024229904A Pending JP2025060876A (ja) 2019-01-23 2024-12-26 抗cd38結合ドメイン

Country Status (9)

Country Link
US (2) US11414496B2 (https=)
EP (1) EP3914358A1 (https=)
JP (2) JP2022518282A (https=)
CN (1) CN113710324B (https=)
AR (1) AR119677A1 (https=)
AU (1) AU2020211407A1 (https=)
CA (1) CA3127624A1 (https=)
TW (1) TWI863959B (https=)
WO (1) WO2020154540A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11414496B2 (en) 2019-01-23 2022-08-16 Takeda Pharmaceutical Company Limited Anti-CD38 binding domains
EP3914610A1 (en) 2019-01-23 2021-12-01 Millennium Pharmaceuticals, Inc. Cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors
US20230312742A1 (en) * 2020-06-17 2023-10-05 Y-Mabs Therapeutics, Inc. CD38 antibodies for the treatment of human diseases
EP4490168A1 (en) * 2022-03-08 2025-01-15 Molecular Templates, Inc. Ctla-4 binding molecules comprising shiga toxin a subunit scaffolds and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
AU723268B2 (en) 1996-09-09 2000-08-24 Zealand Pharma A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998048032A2 (en) 1997-04-21 1998-10-29 Donlar Corporation POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
WO2003073238A2 (en) 2002-02-27 2003-09-04 California Institute Of Technology Computational method for designing enzymes for incorporation of amino acid analogs into proteins
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
WO2005035727A2 (en) 2003-10-09 2005-04-21 Ambrx, Inc. Polymer derivatives
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US7887801B2 (en) 2007-07-13 2011-02-15 Topotarget Germany Ag Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
EP3666795A1 (en) 2013-03-12 2020-06-17 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
BR112015027313A2 (pt) * 2013-04-29 2017-09-26 Teva Pharmaceuticals Australia Pty Ltd anticorpos anti-cd38 e fusões ao interferon alfa-2b atenuado
US20160177284A1 (en) * 2014-01-27 2016-06-23 Molecular Templates, Inc. Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions
CN112851769A (zh) 2014-01-27 2021-05-28 分子模板公司 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
JP6935195B2 (ja) 2014-03-11 2021-09-15 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 結合領域、志賀毒素aサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
ES2809729T3 (es) 2014-03-11 2021-03-05 Molecular Templates Inc Proteínas que comprenden regiones efectoras de la subunidad A de la toxina Shiga próximas al extremo amino terminal y regiones de unión de tipo inmunoglobulina de reconocimiento celular capaces de unirse específicamente a HER2/neu/ErbB2
CN106604934A (zh) 2014-06-11 2017-04-26 分子模板公司 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
EP3253799B1 (en) 2015-02-05 2020-12-02 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
KR20180030085A (ko) 2015-07-26 2018-03-21 몰레큘러 템플레이츠, 인코퍼레이션. 시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
US20190276549A1 (en) * 2016-11-01 2019-09-12 Genmab B.V. Polypeptide variants and uses thereof
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
MX2019008840A (es) 2017-01-25 2019-09-09 Molecular Templates Inc Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
WO2018159615A1 (en) 2017-02-28 2018-09-07 Chugai Seiyaku Kabushiki Kaisha Protein purification with protein l
EP3914610A1 (en) 2019-01-23 2021-12-01 Millennium Pharmaceuticals, Inc. Cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors
US11414496B2 (en) 2019-01-23 2022-08-16 Takeda Pharmaceutical Company Limited Anti-CD38 binding domains
US12462008B2 (en) 2021-04-23 2025-11-04 Beijing Boe Technology Development Co., Ltd. Unlocking control method and device, electronic apparatus, and computer-readable storage medium

Similar Documents

Publication Publication Date Title
JP7138046B2 (ja) 二特異性抗体基幹
CN110382529B (zh) 工程化的异源二聚体蛋白质
JP2022518282A5 (https=)
TWI359027B (en) Bivalent, bispecific antibodies
JP2019528051A (ja) 修飾抗原結合Fab断片及びこれを含む抗原結合分子
HK1246330A1 (zh) 蛋白质纯化
KR102675400B1 (ko) 단백질 정제 방법
JP7812230B2 (ja) ポリペプチド鎖交換による抗体由来ポリペプチドの生成
JP2017534296A5 (https=)
WO2022166728A1 (zh) 双特异性抗体
JP2024507693A5 (https=)
JP7638900B2 (ja) 半減期が延長された活性化可能な治療用多重特異性ポリペプチド
JP7688584B2 (ja) ポリペプチド鎖の交換により活性化される治療用多重特異性ポリペプチド
CN104558181A (zh) 靶向b淋巴瘤细胞的人源单链抗体
KR20230118612A (ko) 헤테로다이머화를 위한 직교 돌연변이
JP2022517549A (ja) 二価の二重特異性抗体およびその製造方法、コードする遺伝子、宿主細胞、組成物
JP2025537782A (ja) 活性化可能なエフェクタードメインを有する組換え結合タンパク質
CN104628851A (zh) 一种抗狂犬病毒的基因工程抗体、其制备方法和应用
JP2025514763A5 (https=)
Rivera-Castro et al. Comparative analysis of manufacturability and binding of various bispecific antibody architectures
WO2026067827A1 (zh) 一种制备异源多聚体的方法及应用
HK40062072B (zh) 通过多肽链交换产生抗体衍生的多肽
WO2026059472A1 (en) Bivalent bispecific antibody and method for producing thereof
JP2025528101A (ja) 多重特異性ポリペプチド複合体
HK40060366B (zh) 通过多肽链交换活化的治疗性多特异性多肽